WASHINGTON - Kidney Cancer Research Alliance (KCCure) President Dena Battle has been elected to the National Cancer Institute’s Renal Task Force to serve as one of two patient advocates on the panel.
New data from the pivotal phase 3 Checkmate 214 trial combining ipilumimab and nivolumab presented at the European Society of Medical Oncology (ESMO) conference in Madrid showed superiority for the combination over Sunitinib (Sutent). This data will likely mean that the IO combination will move to approval for first line stage 4 RCC therapy.
The Kidney Cancer Research Alliance (KCCure) announced today that their first research grant of $100,000 has been awarded to Dr. Wayne Marasco, at Dana Farber Cancer Center for his proposal: CAR T-Cell Factories that change the Tumor Microenvironment to Achieve RCC Cures.
For our part, in honor of World Kidney Cancer Day – we are proud to announce that our first grant of $100,000 is being awarded to Dr. Wayne Marasco at Dana Farber Cancer Center for his continuing efforts to translate CAR T-Cell Therapy into a new treatment for kidney cancer.